RecruitingNot ApplicableNCT07177183

Low Serum Creatinine as a Predictor of Prolonged Mechanical Ventilation and Weaning Failure


Sponsor

University Hospital Ostrava

Enrollment

492 participants

Start Date

Feb 2, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

The main objective of the study is to determine whether a subnormal serum creatinine value upon admission to the Post-ICU Care Unit predicts the need for prolonged ventilatory support. A parallel objective of the study is to determine whether exogenous in-take of the dietary supplement creatine in patients with subnormal serum creatinine value is associated with a shortened duration of ventilatory support and improved patients outcome.


Eligibility

Min Age: 18 Years

Inclusion Criteria2

  • Patients <18 years of age
  • Patients admitted to post-ICU care units at Chronicare Group a.s. in the Czech Republic within 12 months

Exclusion Criteria7

  • Patients who are unlikely to be weaned from ventilatory support.
  • Patients in palliative care or with a survival probability of <3 months
  • Patients with advanced malignancy
  • Patients with a history of chronic kidney disease
  • Patients with a history of chronic liver disease
  • Patients with supranormal serum creatinine on admission to the post-ICU care unit
  • Patients who refused to sign the Informed Consent with participation in the study.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIETARY_SUPPLEMENTDietary supplement creatine

Dietary supplement creatine. The dosage of creatine will be as follows: for the first 7 days after enrolment, the daily dose will be 2x5g. From days 8 to 21, the daily dose will be 1x5g. The substance will be administered orally or through a nasogastric tube.

DIETARY_SUPPLEMENTDietary supplement - placebo

Dietary supplement polydextrose as a placebo. The dosage of placebo will be as follows: for the first 7 days after enrolment, the daily dose will be 2x5g. From days 8 to 21, the daily dose will be 1x5g. The substance will be administered orally or through a nasogastric tube.

OTHERNo intervention

Patients in Group 1 will serve as controls and will receive no intervention, only standard care.


Locations(2)

Chronicare Mund s.r.o.

Brno, Czechia

Chronicare s.r.o.

Milovice, Czechia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07177183


Related Trials